Nutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa Rica
Rhea-AI Summary
Nutriband (NASDAQ: NTRB) announced that the Costa Rica Ministry of Health approved its line of kinesiology tapes for import and sale on March 18, 2026. The approval covers the Company’s Kinesiology Line, AVERSA products and mosquito repellent patches.
The Company said its exclusive Costa Rica distributor, Innomedica CCB S.A., oversaw and financed the regulatory approval process. Nutriband and Innomedica plan to begin ramping up marketing and distribution in Costa Rica following this approval.
Positive
- Ministry of Health approval for import and sale (Mar 18, 2026)
- Exclusive distribution agreement with Innomedica CCB
- Innomedica financed and oversaw regulatory approval process
Negative
- None.
News Market Reaction – NTRB
In the Mar 18 session, NTRB gained 0.51%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 17 | Distribution agreement | Positive | +4.0% | Exclusive Costa Rica distribution deal for AVERSA fentanyl and sports tapes. |
| Jan 30 | Shareholder meeting recap | Positive | +6.0% | Annual meeting highlights AVERSA progress, patents, manufacturing scale-up, and warrants. |
| Dec 31 | CEO shareholder letter | Positive | -3.0% | CEO reviews 2025 milestones, AVERSA progress, and 2026 outlook. |
| Dec 29 | Subsidiary sale | Positive | +16.0% | Agreement to sell 90% of Pocono Pharmaceutical for $5M to fund AVERSA. |
| Dec 18 | Technology LOI | Positive | +3.0% | Non-binding LOI with Qvanta to explore advanced tech for abuse-deterrent R&D. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company-specific announcements have usually been followed by positive price reactions, with one notable divergence on a broadly positive shareholder letter.
Over the past months, Nutriband has focused on AVERSA development, capital structure, and strategic partnerships. A $5M sale of 90% of Pocono Pharmaceutical to EarthVision Bio on Dec 31, 2025 funded AVERSA Fentanyl development and coincided with a 16.04% move. Subsequent events, including a shareholder meeting recap on Jan 24, 2026 and a Costa Rica distribution agreement on Feb 17, 2026, generally aligned with positive price reactions. Today’s Costa Rica regulatory approval for Kinesiology Tapes and related products continues that commercial rollout theme in the same market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The Company recently announced an exclusive distribution agreement with Innomedica CCB S.A. for its Kinesiology Line, AVERSA products and Mosquito repellent patches
ORLANDO, Fla., March 18, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) today announced that The Costa Rica Ministry of Health has approved the Company’s line of Kinesiology Tapes for import and Sale. Innomedica CCB, the company’s exclusive distribution partner for Costa Rica oversaw and financed the regulatory approval process.
The Company, partnering with Innomedica plans to begin ramping up marketing efforts for these products and its mosquito repellant patch line following this latest approval.
About AVERSA™ Abuse-Deterrent Transdermal Technology
Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, including opioids and stimulant drugs, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's periodic and current reports on Form 10-K, Forms 10-Q and 8-K and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information:
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
SOURCE: Nutriband Inc.
